Latest Feature

Kimberly-Clark readies Halyard Health medical device spinout

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

HART CEO David Green on the transformative potential for regenerative medicine

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Wound care by the numbers: Q&A with Alliqua CEO Dave Johnson

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

Podcast: Medtech legends and leaders on the state of medical device innovation

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.

CardioMEMS took 11 years to pay off, but for Boston Millennia it was worth it

Boston Millennia's managing general partner Dana Callow discusses the 11-year journey to bring CardioMEMs implantable heart monitor to market and what his venture capital firm sees for the future of medtech investment.

Subscribe to the MassDevice
Newsletter
Enter your email:

Need Medtech news in a minute? We Deliver!


MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

TCT 2014: Boston Scientific's 1-year data on Lotus TAVI device

September 16, 2014 by Brad Perriello

Boston Scientific's Lotus replacement heart valve shows low leakage rates and no instances of moderate or severe leakage, a problem that plagued the earlier generation of transcatheter aortic valve implants.

TCT 2014: Boston Scientific's 1-year data on Lotus TAVI device

Another J&J exec pressed in lawsuit over Pinnacle hip implant

September 16, 2014 by Brad Perriello

The plaintiff's lawyer in the 1st product liability trial over DePuy's Pinnacle hip replacement grills another Johnson & Johnson executive, worldwide clinical research vice president Pamela Plouhar, the at DePuy, over the metal-on-metal implants.

Another J&J exec pressed in lawsuit over Pinnacle hip implant

Apple's HealthKit takes center stage in 2 studies | MassDevice.com On Call

September 16, 2014 by Arezu Sarvestani

Technology titan Apple provides its new mobile HealthKit data-aggregation app to researchers at Standford and Duke Universities.

MassDevice.com On Call

MASSDEVICE ON CALL — Apple (NSDQ:AAPL) is driving home its growing partnership with the healthcare industry by lending its new HealthKit iPhone application to researchers at Stanford and Duke Universities.

Funding: InSightec raises $12.5M from Chinese backers

September 16, 2014 by Arezu Sarvestani

A group of Chinese investors pays $12.5 million to acquire about 5% of Israeli ultrasound therapy devices maker InSightec.

Funding: Insightec raises $12.5M from Chinese backers

Israeli device maker InSightec added $12.5 million to its coffers thanks to the support of Chinese backers, the firm's parent company announced.

TCT 2014 Roundup

September 15, 2014 by Brad Perriello

A roundup of studies released at the annual Transcatheter Cardiovascular Therapies conference in Washington this week.

TCT 2014 Roundup

Here's a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:

Digital health: Medtronic launches heart-monitoring patch

September 15, 2014 by Arezu Sarvestani

Medtech titan Medtronic launches U.S. sales of the SEEQ wearable heart monitor it picked up in this year's acquisition of Corventis.

Digital health: Medtronic launches wearable heart monitor

Medtronic (NYSE:MDT) is poised to make a big splash in remote patient monitoring with the commercial launch of its SEEQ skin-worn heart monitoring patch.

TCT 2014: Is renal denervation dead or alive?

September 15, 2014 by Brad Perriello

Is renal denervation for hypertension dead or alive? Experts agree that more studies are needed.

TCT 2014: Is renal denervation dead or alive?

The efficacy of renal denervation is in doubt and should be confirmed or ruled out in treating resistant hypertension, according to an expert panel in a debate over the once high-flying technology at the Transcatheter Cardiovascular Therapeutics conference in Washington.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp